Home/Pipeline/Xanamem (emestedastat)

Xanamem (emestedastat)

Alzheimer's Disease

Phase 2b/3Active

Key Facts

Indication

Alzheimer's Disease

Phase

Phase 2b/3

Status

Active

Company

Actinogen Medical, Actinogen Medical, Actinogen Medical

About Actinogen Medical

Australian‑focused biotech advancing a brain‑cortisol inhibitor for Alzheimer’s and depression.

View full company profile

About Actinogen Medical

Australian‑focused biotech advancing a brain‑cortisol inhibitor for Alzheimer’s and depression.

View full company profile

About Actinogen Medical

Australian‑focused biotech advancing a brain‑cortisol inhibitor for Alzheimer’s and depression.

View full company profile

Therapeutic Areas

Neurology Psychiatry

Other Alzheimer's Disease Drugs

Drug	Company	Phase	Status
NUZ-001	Neurizon Therapeutics	Preclinical	Active
ALZN002	Alzamend Neuro	Preclinical	Research
P021	Phanes Biotech	Preclinical	Active
PB43D	Phanes Biotech	Preclinical	Active
UB-311	Vaxxinity	Phase 2	Active
Lecanemab	BioArctic	Launched	Active (Commercial)
BAN2401	BioArctic	Preclinical	Active
Undisclosed Programs	Johnson and Johnson Innovative Medicine	Pipeline	Active
MK-6240 (florquinitau)	Lantheus Medical Imaging	Regulatory Filing	Filed
NAV-4694 (flutafuranol)	Lantheus Medical Imaging	Phase 3	Active
LNTH-2620/PI-2620	Lantheus Medical Imaging	Phase 3	Recruiting
itMSCs	Stemedica Cell Technologies	Clinical Development	Active